A Long-term Extension Study of Ustekinumab in Pediatric Participants

Study Purpose

The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 2 Years - 17 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Must have completed the dosing planned in the primary pediatric ustekinumab study.
  • - Benefit of continued ustekinumab therapy (that is, a clinical response or clinical remission as defined in the primary study at the final efficacy visit of the primary study) - Parent(s) (preferably both if available or as per local requirements), legal guardian(s) or their legally acceptable representative must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study.
Assent is also required of children capable of understanding the nature of the study (typically 7 years of age and older) as described in Informed Consent Process. An adolescent who signs the assent form will be given the opportunity to sign an adult ICF at a later visit when they reach the age of majority during the study to indicate that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
  • - Must be willing and able to adhere to the lifestyle restrictions specified in this protocol.
  • - Females of childbearing potential must have a negative urine pregnancy test at enrollment and prior to study intervention administration.

Exclusion Criteria:

  • - Are pregnant, nursing, or planning pregnancy or fathering a child.
  • - Have had any of (a) confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 [COVID-19]) infection (test positive), or (b) suspected SARS-CoV-2 infection (clinical features without documented test results), or (c) close contact with a person with known or suspected SARS-CoV-2 infection: Exception: (i) may be included with a documented negative result for a validated SARS-CoV-2 test: obtained at least 2 weeks after conditions (a), (b), (c) above (timed from resolution of key clinical features if present, example, fever, cough, dyspnea) and (ii) with absence of all conditions (a), (b), (c) above during the period between the negative test result and the baseline study visit.
  • - Taken any disallowed therapies as noted in the primary study, before the planned first long-term extension (LTE) dose of study intervention.
  • - Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  • - Participants who receive a live vaccination may be permitted to remain in the study, if approved by the sponsor and study intervention is held for a period of time specified by the sponsor.
Receipt of a live severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) vaccine (against the virus that causes Coronavirus Disease 2019 [COVID-19]) is not automatically an exclusion criterion and must be discussed with the medical monitor

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05092269
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Janssen Research & Development, LLC
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Janssen Research & Development, LLC Clinical Trial
Principal Investigator Affiliation Janssen Research & Development, LLC
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Argentina, Belgium, France, Germany, Hungary, Japan, Poland, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Arms & Interventions

Arms

Experimental: Ustekinumab

Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004, CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Participants enrolling from the Exposure Optimization Substudy may be eligible to remain on the every 4 weeks (q4w) dosing regimen.

Interventions

Drug: - Ustekinumab

Ustekinumab will be administered as a SC injection.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Atlanta, Georgia

Status

Recruiting

Address

Children's Center For Digestive Healthcare, Llc

Atlanta, Georgia, 30342

Mount Sinai, New York, New York

Status

Recruiting

Address

Mount Sinai

New York, New York, 10029

International Sites

Hospital de Ninos de Cordoba, Cordoba, Argentina

Status

Recruiting

Address

Hospital de Ninos de Cordoba

Cordoba, , X5014FTO

San Miguel De Tucuman, Argentina

Status

Recruiting

Address

Centro de Investigaciones Medicas Tucuman

San Miguel De Tucuman, , T4000AXL

Huderf, Bruxelles, Belgium

Status

Recruiting

Address

Huderf

Bruxelles, , 1020

Cliniques Universitaires Saint Luc, Bruxelles, Belgium

Status

Recruiting

Address

Cliniques Universitaires Saint Luc

Bruxelles, , 1200

UZ Gent, Gent, Belgium

Status

Recruiting

Address

UZ Gent

Gent, , 9000

UZ Brussel, Jette, Belgium

Status

Recruiting

Address

UZ Brussel

Jette, , 1090

Uz Gasthuisberg, Leuven, Belgium

Status

Recruiting

Address

Uz Gasthuisberg

Leuven, , 3000

Hôpital Necker, Paris, France

Status

Recruiting

Address

Hôpital Necker

Paris, , 75015

Universitaetsklinikum der RWTH Aachen, Aachen, Germany

Status

Recruiting

Address

Universitaetsklinikum der RWTH Aachen

Aachen, , 52074

Berlin, Germany

Status

Recruiting

Address

Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

Berlin, , 13353

Semmelweis Egyetem, Budapest, Hungary

Status

Recruiting

Address

Semmelweis Egyetem

Budapest, , 1083

Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary

Status

Recruiting

Address

Debreceni Egyetem Klinikai Kozpont

Debrecen, , 4032

Miskolc, Hungary

Status

Recruiting

Address

Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz

Miskolc, , 3526

Nyiregyhaza, Hungary

Status

Recruiting

Address

Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz

Nyiregyhaza, , 4400

Szegedi Tudomanyegyetem, Szeged, Hungary

Status

Recruiting

Address

Szegedi Tudomanyegyetem

Szeged, , 6720

Juntendo University Hospital, Bunkyo Ku, Japan

Status

Recruiting

Address

Juntendo University Hospital

Bunkyo Ku, , 113 8431

Gunma University Hospital, Gunma, Japan

Status

Recruiting

Address

Gunma University Hospital

Gunma, , 371-0034

Kurume University Hospital, Kurume, Japan

Status

Recruiting

Address

Kurume University Hospital

Kurume, , 830-0011

Saitama Childrens Medical Center, Saitama shi, Japan

Status

Recruiting

Address

Saitama Childrens Medical Center

Saitama shi, , 330-8777

Miyagi Children's Hospital, Sendai, Japan

Status

Recruiting

Address

Miyagi Children's Hospital

Sendai, , 989-3126

Setagaya Ku, Japan

Status

Recruiting

Address

National Center for Child Health and Development

Setagaya Ku, , 157 8535

Mie University Hospital, Tsu, Japan

Status

Recruiting

Address

Mie University Hospital

Tsu, , 514 8507

Krakow, Poland

Status

Recruiting

Address

Uniwersytecki Szpital Dzieciecy w Krakowie

Krakow, , 30-663

Korczowski Bartosz Gabinet Lekarski, Rzeszow, Poland

Status

Recruiting

Address

Korczowski Bartosz Gabinet Lekarski

Rzeszow, , 35-302

GASTROMED Sp. z o.o., Torun, Poland

Status

Recruiting

Address

GASTROMED Sp. z o.o.

Torun, , 87-100

Medical Network, Warszawa, Poland

Status

Recruiting

Address

Medical Network

Warszawa, , 04-501

Instytut Pomnik Centrum Zdrowia, Warszawa, Poland

Status

Recruiting

Address

Instytut Pomnik Centrum Zdrowia

Warszawa, , 04-730

Birmingham Children's Hospital, Birmingham, United Kingdom

Status

Recruiting

Address

Birmingham Children's Hospital

Birmingham, , B4 6NH

Addenbrookes Hospital, Cambridge, United Kingdom

Status

Recruiting

Address

Addenbrookes Hospital

Cambridge, , Cb2 2qq

Royal London Hospital, London, United Kingdom

Status

Recruiting

Address

Royal London Hospital

London, , E1 1BB